Estrogen receptor-beta: why may it influence clinical outcome in estrogen receptor-alpha positive breast cancer?
In the previous issue of the journal, Lin and coworkers present data demonstrate that increased expression of estrogen receptor (ER)-beta in ER-alpha-positive breast cancer cells antagonizes a defined group of ER-alpha/estrogen stimulated genes that are involved in cell cycle regulation and DNA replication. Similar expression patterns for these genes were found human ER-alpha positive breast tumors expressing higher levels or ER-beta, and this correlated with better clinical outcome. The implications for these data, which suggest that ER-beta is a positive actor and diagnostic marker for therapeutic outcome, are discussed.
Shupnik
Margaret A
MA
D001943:Breast Neoplasms / Q000139:chemically induced / Q000473:pathology* / Q000628:therapy*; D002453:Cell Cycle; D004261:DNA Replication / Q000235:genetics; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors / Q000502:physiology*; D047629:Estrogen Receptor beta / Q000502:physiology*; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D012307:Risk Factors; D014158:Transcription, Genetic
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D004967:Estrogens